A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases.

• Conditions: Myeloproliferative Disease; Pulmonary Hypertension
• Interventions: Other: myeloproliferative disease

• Registration Number: NCT01884974
• Lead Sponsor: Carmel Medical Center

Brief Summary

Pulmonary hypertension (PH) is defined as a group of diseases characterised by an elevated mean pulmonary artery pressure (Ppa) ≥25 mmHg at rest. Recently, chronic myeloproliferative diseases (CMPD) associated with pulmonary hypertension were included in the group 5 category, corresponding to PH for which the aetiology is unclear and/or multifactorial. CMPD include chronic myelogenous leukaemia, chronic neutrophilic leukaemia and chronic eosinophilic leukaemia (which primarily express a myeloid phenotype and polycythaemia vera), idiopathic myelofibrosis, and essential thrombocytosis in which erythroid or megakaryocytic hyperplasia predominates.

The purpose of this research:

1. Assess Prevalence of PH in patients with CMPD in Northern Israel

2. Describe the demographics and clinical course in patients with CMPD who are diagnosed with PH.

Detailed Description

study will include the following:

* sex

* age

* BMI

* ethnicity

* age diagnosed with Myeloproliferative disease

* clinical manifestations of the myeloproliferative disease

* JAK2 mutation

* known hematological complications

Study Timeline

• Study First Submitted: 2013-06-20
• Study First Submitted QC: 2013-06-21
• Study First Posted: 2013-06-24
• Study Start: 2013-07
• Status Verified: 2015-06
• Last Update Submitted: 2015-06-15
• Last Update Posted: 2015-06-16
• Primary Completion: 2016-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1. consenting patients diagnosed with a myeloproliferative disease

Exclusion Criteria

1. Refusal to have an echocardiogram or answer the St. George respiratory questionnaire

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
myeloproliferative disease	myeloproliferative disease	Patients with Myeloproliferative Diseases as specified under inclusion and exclusion criteria

Primary Outcome Measures

Name	Time	Method
pulmonary hypertension	1 year	all patients with myeloproliferative diseases in the study will be evaluated by an echocardiogram. Pulmonary hypertension will be considered when the average pulmonary arterial pressure is equal or above 25 mmHg.

Secondary Outcome Measures

Name	Time	Method
St George Respiratory Questionnaire	1 year

Trial Locations

Locations (1)

Pulmonology Institute, Carmel Medical Center; 🇮🇱 Haifa, Israel